Oncologia Novità by Xagena
Updates in Oncology
I costi elevati dei farmaci, soprattutto quelli oncologici, impongono scelte. Gran Gretagna: le decisioni di NICE & CDF [ Cancer Drugs Fund ]
Inghilterra: Stivarga rimane nel Cancer Drugs Fund; rigettati i ricorsi di Eisai e di Eli Lilly
NHS / NICE
Revisione degli antitumorali da parte del NHS in base alla Evidence-based Medicine
Il Servizio sanitario inglese, NHS, ha aumentato il budget per il comparto farmaci antitumorali da 280 milioni di sterline nel…
NICE – Olaparib per il tumore dell’ovaio, tube di Falloppio e peritoneale: prezzo troppo alto per il beneficio che può fornire ai pazienti
Il NICE ( National Institute for Health and Care Excellence ) ha aperto una consultazione sulla bozza di determinazione riguardante…
Cancro del polmone non-a-piccole cellule, squamoso, in fase avanzata: l’FDA ha approvato Opdivo, il primo inibitore PD-1
L’Agenzia regolatoria degli Stati Uniti, FDA ( Food and Drug Administration ) ha approvato Opdivo ( Nivolumab ), un inibitore PD-1, nel trattamento del tumore al polmone non-a-piccole cellule ( NSCLC …
Efficacia di Nivolumab in monoterapia nel tumore del polmone non-a-piccole cellule, precedentemente trattato
Nivolumab ( Opdivo ) ha prodotto risposte durature e prolungata sopravvivenza globale nei pazienti con cancro del polmone non-a-piccole cellule, trattato in precedenza.
USA: presentata domanda per l’approvazione del regime Opdivo più Yervoy nei pazienti con melanoma avanzato, non-trattati in precedenza
Bristol-Myers Squibb ( BMS ) ha annunciato che la FDA ( Food and Drug Administration ) ha accettato la domanda di registrazione supplementare ( supplemental Biologics License Application; sBLA ) per i …
OncoDigest
MED15, a potential prognostic marker for recurrence of head and neck squamous cell carcinoma
A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma ( HNSCC ). MED15 ov …
Breast surgery offers less survival benefit for patients with low-grade ductal carcinoma in-situ
In a study, researchers from Brigham and Women’s Hospital ( BWH ) ( Boston, Massachusetts; USA ) have reported that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcino …
Therapy
Cancer immunotherapy plus targeted therapy, an approach with curative possibilities
A review, titled Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, from researchers at The University of Texas MD Anderson Cancer Center published i ..
CDF: Regorafenib for treatment of adult patients with advanced gastro-intestinal stromal tumours ( GIST ) after failure of at least previous Imatinib and Sunitinib
The application was for Regorafenib ( Stivarga ) to remain in the Cancer Drugs Fund ( CDF ) as treatment for patients with non-resectable or metastatic gastrointestinal stromal tumours ( GISTs ) who w …
Patients with non-squamous non-small cell lung cancer – Pemetrexed chemotherapy as maintenance therapy after 1st line treatment with the combination of Cisplatin and Pemetrexed in: data are insufficient
Cancer Drugs Fund ( CDF ) Panel has assessed the application was for single agent Pemetrexed ( Alimta ) to remain in the CDF as maintenance treatment for patients with locally advanced or metastatic …
Eribulin as single agent 3rd line chemotherapy for locally advanced or metastatic breast cancer, removed from CDF list
Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF list as 3rd line chemotherapy for patients with locally advanced or metastatic breast c …
Pemetrexed chemotherapy as 2nd line treatment for patients with non- squamous non-small cell lung cancer: data are insufficiently robust
Cancer Drugs Fund ( CDF ) Panel has assessed the application for single agent Pemetrexed ( Alimta ) to remain in the CDF as 2nd line treatment for patients with non-squamous ( NS ) non-small cell lun …
NICE has recommended Vargatef in combination with Docetaxel, as a new treatment option for patients with locally advanced metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy
Cancer immunotherapy
Patients with advanced melanoma: safety profile of Nivolumab
Nivolumab ( Opdivo ) is a programmed death-1 ( PD-1 ) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in patients with melano …
Patients with Platinum-resistant ovarian cancer treated with Nivolumab: durable tumor remission
Programmed death-1 ( PD-1 ) is a co-inhibitory receptor expressed on activated T cells which regulates antitumor immunity. Nivolumab ( Opdivo ) is a fully-humanized IgG4 that blocks the engagement o …
Melanoma patients with untreated brain metastases: safety and activity of Pembrolizumab
Brain metastases develop in 40% of metastatic melanoma patients. Untreated brain metastases exclude from most clinical trials. In prior trials, treatment of metastatic melanoma with Pembrolizumab ( Ke …
Patients from a squamous cell carcinoma of the head and neck: safety and efficacy of MEDI4736, an anti-PD-L1 antibody
Outcomes are poor for patients with recurrent / metastatic squamous cell carcinoma of the head and neck ( SCCHN ), and new treatments are needed. An ongoing phase I/II, multicenter, open-label study …
Patients with melanoma that progressed on Ipilimumab: survival, biomarker, and toxicity analysis of Nivolumab
PD-1 antibody, Nivolumab ( Opdivo ), was administered with/without a multi-peptide vaccine to 126 patients ( pts ) with unresectable melanoma that failed at least one regimen and were Ipilimumab ( Yer …
Advanced melanoma: clinical characteristics predictive of response to Pembrolizumab
Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma and in other cancers. Factors predictive of response remain vaguely defined. Researchers have reported on clinical ch …